Invitae

Ciitizen’s mission is to provide Earth’s 7.3 billion citizens with control of their complete health information and give them the choice of sharing it with whomever they want. Period. With this new ownership, patients can share their health history with caregivers, share for second opinions, and with companies/researchers who may hold the answer to their treatment. All patients have a right to all of their health information, yet existing portals pull only minimal clinical information from a fraction of health care institutions. Current “interoperability” initiatives leave the patient out of the picture and often rely on armies of manual labor to extract key health insights from unstructured textual data—an expensive model which doesn’t scale. In the near future, citizens will walk into a clinical facility and, with a simple tap of a mobile device, release their health information to themselves, where Ciitizen normalizes unstructured data from across the healthcare ecosystem into actionable visualizations for patients, their caregivers, and clinicians. Ciitizen has assembled an all-star team, led by its CEO, Anil Sethi (last company was sold to Apple) and is backed by a strong investment team led by Andreessen Horowitz, Verily, Section 32 and others.

One Codex is a data platform for applied microbial genomics, enabling new and valuable applications in clinical diagnostics, food safety, and biosecurity.

ArcherDX, Inc. is a genomics company based in Boulder, Colorado, specializing in the development and commercialization of advanced molecular pathology products and services. The company focuses on next-generation sequencing technologies to enhance genetic mutation detection, offering a range of research products such as VariantPlex, FusionPlex, LiquidPlex, and Immunoverse. ArcherDX's proprietary Anchored Multiplexed PCR (AMP™) chemistry, combined with powerful bioinformatics software, allows for efficient identification of genetic mutations, including gene fusions and point mutations. The company also provides customization services for clinical and biopharmaceutical customers through its assay designer platform, enabling the development of personalized applications. Its products are primarily aimed at academic and reference laboratories, biopharmaceutical firms, and contract research organizations, supporting therapy optimization and cancer monitoring. Founded in 2013, ArcherDX operates as a subsidiary of Invitae Corporation.

Genelex Corporation, based in Seattle, Washington, operates as a DNA testing laboratory specializing in pharmacogenetic testing. Founded in 1987, the company provides a personalized medication management program that includes DNA sensitivity testing and the GeneMedRx software, which assesses potential drug-drug and drug-gene interaction risks based on genetic profiles. Genelex also offers a range of services, including parentage and forensic DNA testing, ancestry DNA testing, and clinical trial genotyping. Additionally, the company markets various at-home and legally admissible DNA tests, such as grandpaternity, maternity, and paternity tests, alongside predictive genetic assessments. Genelex is dedicated to reducing the risk of adverse drug events through its innovative testing and analytical capabilities. As of April 2020, Genelex operates as a subsidiary of Invitae Corporation.

Diploid is a provider of biotechnology services.

Clear Genetics is a digital health company dedicated to the thoughtful integration of genetics into routine patient care. Clear Genetics partners with health systems, labs and academic institutions to increase patient access to genetic counseling and testing.

Headquartered in South San Francisco, Jungla is a biotechnology company delivering robust and scalable results for clinical genetic and genomic testing. To achieve this, Jungla develops and combines advances in functional genomics, computational biophysics, and computer science to proactively inform on the risk of variants in our genome. Jungla aims to empower clinical genetic testing with quantitative, model-driven guidance to complement and enhance observational data. Whereas existing solutions routinely used in the market have demonstrably poor accuracies, Jungla delivers robust, scalable, and auditable support with dramatically higher accuracies and increasingly mechanistic cellular and biophysical insights. We are supported by leading technology and healthcare investors.

Singular Bio's technology provides single molecule analysis of a patient's DNA, giving exquisite sensitivity for detecting many common conditions. The company's mission is to expand access to fundamental healthcare information by making advanced genetic tests available to everyone.

Good Start Genetics, Inc. is a molecular diagnostics company based in Cambridge, Massachusetts, focused on genetic screening for inherited diseases. Founded in 2007, the company aims to transform reproductive medicine by providing physicians and patients with actionable insights into inherited genetic disorders. Good Start Genetics offers a range of services, including EmbryVu, a preimplantation genetic screening test designed to enhance in vitro fertilization outcomes by identifying suitable embryos for implantation. The company employs advanced next-generation DNA sequencing technology, along with other established genetic screening methods, to deliver high carrier detection rates. Additionally, through its GoodStart Select program, it provides a comprehensive menu of genetic carrier screening tests for both known and novel mutations, all supported by a commitment to customer care and genetic counseling. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.

CombiMatrix Corporation develops proprietary technologies, products, and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology, and defense and homeland security. Its technologies include a platform to produce user-defined, in-situ synthesized, and oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations, and proteins. The company�s products and services include CustomArray platform, an oligonucleotide array for genetic studies; DNA Array Synthesizer, an instrument that enables researchers to fabricate DNA arrays to their specifications; stripping reagents, which enable researchers to re-use microarrays; ElectraSense Reader, an electrochemical scanning instrument; and comparative genomic hybridization arrays, which are used for research and molecular diagnostic applications. It also offers proprietary molecular synthesis and screening methods for the discovery of potential new drugs. In addition, it operates as a diagnostics reference laboratory, which provides genetic diagnostics services through the use of arrays that utilize bacterial artificial chromosomes that enable genetic analysis to physicians, hospitals, and clinics. Further, the company develops a series of compounds to address various oncology-related diseases. Additionally, it involves in the development, manufacture, and sale of biosensor systems and technology for national defense and homeland security. The company sells its products and services directly, with partners, and through distributors to customers in the United States, Europe, and Asia. CombiMatrix Corporation was founded in 1995 and is based in Mukilteo, Washington.

CancerGene Connect is a developer of a cloud-based genetic assessment platform that focuses on collecting, assessing, and managing genetic family histories. The platform enhances genetic counseling programs by streamlining the collection of family medical histories and facilitating cancer risk assessments. This innovative approach allows clinicians to dedicate more time to addressing patient risks, as it significantly reduces the time spent on organizing data. By leveraging evolving technology, CancerGene Connect aims to create powerful connections between patients and healthcare providers, ultimately improving the overall effectiveness of cancer risk management.

AltaVoice is a patient-centered data company based in Silicon Valley that focuses on optimizing the search for better treatments for various diseases. The company builds and hosts Patient Insights Networks (PINs), which are designed to efficiently collect, curate, and share health data reported by patients and clinicians. By collaborating with drug developers, advocacy organizations, and academic researchers, AltaVoice facilitates the unification of data collection efforts while ensuring that advocacy organizations maintain their brand presence. Their PINs enable faster delivery of patient insights compared to traditional registries and contract research organizations. Since its establishment in 2007, AltaVoice has developed programs for over 400 diseases, working with more than 100 advocacy groups, as well as institutions like the NIH and PCORI. The company gained recognition for its innovative contributions to the field, including an invitation to participate in the Cancer Moonshot events at the White House in 2016.